Patients with a disease called hyperparathryoidism have high levels of PTH (the drug in Forteo) and have no increased risk for cancer.
Izigulana ezinengxaki yesifo sokukhupha itharoyidi ngokugqithisileyo zinamaqondo aphezulu ePTH (iyeza elifumaneka kwiForteo) kwaye azinamngcipheko unyukileyo wokuphathwa ngumhlaza.